Skip to main content
19 November 2026

LOTTE Biologics Strengthens CDMO Growth with Major Manufacturing Deal

LOTTE Biologics announced a major commercial manufacturing agreement with a global pharmaceutical company, marking a significant milestone in the commercialization of its Songdo Bio Campus.

The agreement represents the first major commercial manufacturing commitment for Songdo Plant 1, secured ahead of its operational launch. Under the partnership, LOTTE Biologics will provide integrated drug substance and drug product manufacturing services for key products in the customer's portfolio, with commercial production targeted to begin in 2027.

Early Commercial Success Validates Growth Strategy

Securing commercial manufacturing volume while the facility is still under development underscores customer confidence in LOTTE Biologics' technical expertise, execution capabilities, and long-term supply reliability.

By aligning capacity expansion with customer commitments from the outset, LOTTE Biologics is accelerating its path to commercialization and establishing a strong foundation for sustainable growth.

slot gacor